$TGTX
TG THERAPEUTICS, INC.

2022 Q2 Form 10-Q Financial Statement

#000155837022008130 Filed on May 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q4
Revenue $594.0K $2.016M $2.321M
YoY Change -61.55% 154.22% 5702.5%
Cost Of Revenue $23.00K $237.0K $210.0K
YoY Change -84.46% 70.5%
Gross Profit $571.0K $1.779M $2.111M
YoY Change -59.13% 172.02%
Gross Profit Margin 96.13% 88.24% 90.95%
Selling, General & Admin $12.64M $20.61M $32.41M
YoY Change -62.85% -22.99% -26.1%
% of Gross Profit 2213.31% 1158.46% 1535.39%
Research & Development $26.87M $48.04M $62.65M
YoY Change -40.11% -23.86% 45.82%
% of Gross Profit 4706.48% 2700.51% 2967.6%
Depreciation & Amortization $78.00K $76.00K $80.00K
YoY Change 18.18% 28.81% 60.0%
% of Gross Profit 13.66% 4.27% 3.79%
Operating Expenses $39.51M $68.89M $95.06M
YoY Change -50.01% -23.45% 9.49%
Operating Profit -$38.94M -$66.87M -$92.95M
YoY Change -49.75% -25.03%
Interest Expense -$3.017M $2.664M -$1.079M
YoY Change -285.89% 40.36% -16.36%
% of Operating Profit
Other Income/Expense, Net $1.448M -$2.141M $688.0K
YoY Change -244.08% 50.14% -558.67%
Pretax Income -$40.51M -$69.01M -$93.34M
YoY Change -48.39% -23.85% 5.8%
Income Tax
% Of Pretax Income
Net Earnings -$40.51M -$69.01M -$93.34M
YoY Change -48.39% -23.85% 5.8%
Net Earnings / Revenue -6819.87% -3423.26% -4021.46%
Basic Earnings Per Share -$0.30 -$0.51
Diluted Earnings Per Share -$300.6K -$0.51 -$704.1K
COMMON SHARES
Basic Shares Outstanding 144.4M 134.4M 142.9M
Diluted Shares Outstanding 134.8M 134.4M

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $195.7M $233.2M $314.8M
YoY Change -55.87% -55.48% -48.01%
Cash & Equivalents $147.1M $185.7M $298.9M
Short-Term Investments $48.64M $47.53M $15.88M
Other Short-Term Assets $6.763M $4.020M $2.884M
YoY Change 129.25% -16.32% 166.3%
Inventory
Prepaid Expenses
Receivables $88.00K $903.0K $1.389M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $202.6M $242.2M $331.0M
YoY Change -55.49% -54.73% -45.9%
LONG-TERM ASSETS
Property, Plant & Equipment $10.96M $526.0K $600.0K
YoY Change 1736.35% 7.79% 24.74%
Goodwill $799.0K $799.0K
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments $36.08M $47.47M $35.53M
YoY Change 182.81%
Other Assets $1.266M $1.265M $1.264M
YoY Change 0.4% -2.69% -2.77%
Total Long-Term Assets $49.11M $60.81M $48.66M
YoY Change 86.49% 344.34% 250.05%
TOTAL ASSETS
Total Short-Term Assets $202.6M $242.2M $331.0M
Total Long-Term Assets $49.11M $60.81M $48.66M
Total Assets $251.7M $303.0M $379.6M
YoY Change -47.72% -44.77% -39.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $37.22M $49.67M $51.29M
YoY Change -7.47% 16.05% 38.63%
Accrued Expenses $4.362M $3.115M $11.60M
YoY Change -56.44% -38.92% 14.88%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $975.0K
YoY Change -100.0% -100.0% -95.6%
Total Short-Term Liabilities $43.33M $54.66M $65.38M
YoY Change -50.51% -40.91% -25.32%
LONG-TERM LIABILITIES
Long-Term Debt $68.95M $67.25M $66.79M
YoY Change 765.58%
Other Long-Term Liabilities $10.36M $10.74M $10.30M
YoY Change -3.37% -1.5% -6.33%
Total Long-Term Liabilities $79.31M $67.25M $66.79M
YoY Change 639.85% 516.96% 765.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $43.33M $54.66M $65.38M
Total Long-Term Liabilities $79.31M $67.25M $66.79M
Total Liabilities $122.6M $132.6M $142.5M
YoY Change 24.79% 28.26% 34.04%
SHAREHOLDERS EQUITY
Retained Earnings -$1.400B -$1.329B
YoY Change 27.27% 35.5%
Common Stock $145.0K $143.0K
YoY Change 2.11% 1.42%
Preferred Stock
YoY Change
Treasury Stock (at cost) $234.0K $234.0K
YoY Change 0.0% 17.0%
Treasury Stock Shares $41.31K $41.31K
Shareholders Equity $129.0M $170.4M $237.2M
YoY Change
Total Liabilities & Shareholders Equity $251.7M $303.0M $379.6M
YoY Change -47.72% -44.77% -39.32%

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q4
OPERATING ACTIVITIES
Net Income -$40.51M -$69.01M -$93.34M
YoY Change -48.39% -23.85% 5.8%
Depreciation, Depletion And Amortization $78.00K $76.00K $80.00K
YoY Change 18.18% 28.81% 60.0%
Cash From Operating Activities -$49.12M -$68.69M -$86.91M
YoY Change -18.36% -15.57% 67.04%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $7.000K -$80.00K
YoY Change -100.0% -89.55% -50.0%
Acquisitions
YoY Change
Other Investing Activities $10.38M -$43.66M $3.368M
YoY Change -551.85% 9603.11% -106.49%
Cash From Investing Activities $10.38M -$43.67M $3.288M
YoY Change -518.68% 8396.3% -106.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 135.0K -850.0K 56.00M
YoY Change -101.89% 1445.45% -86.12%
NET CHANGE
Cash From Operating Activities -49.12M -68.69M -86.91M
Cash From Investing Activities 10.38M -43.67M 3.288M
Cash From Financing Activities 135.0K -850.0K 56.00M
Net Change In Cash -38.60M -113.2M -27.62M
YoY Change -44.7% 38.19% -109.23%
FREE CASH FLOW
Cash From Operating Activities -$49.12M -$68.69M -$86.91M
Capital Expenditures $0.00 $7.000K -$80.00K
Free Cash Flow -$49.12M -$68.70M -$86.83M
YoY Change -18.13% -15.63% 67.4%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
134400500
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
131898626
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001001316
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-32639
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
TG THERAPEUTICS, INC.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
36-3898269
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
36-3898269
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
2 Gansevoort Street, 9th Floor
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10014
CY2022Q1 dei City Area Code
CityAreaCode
212
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
554-4484
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2022Q1 dei Trading Symbol
TradingSymbol
TGTX
CY2022Q1 dei Trading Symbol
TradingSymbol
TGTX
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
144435369
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
185676000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
298887000
CY2022Q1 us-gaap Short Term Investments
ShortTermInvestments
47525000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
15876000
CY2022Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
903000
CY2021Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
1389000
CY2022Q1 tgtx Prepaid Research And Development
PrepaidResearchAndDevelopment
4092000
CY2021Q4 tgtx Prepaid Research And Development
PrepaidResearchAndDevelopment
11929000
CY2022Q1 us-gaap Other Assets Current
OtherAssetsCurrent
4020000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2884000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
242216000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
330965000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1265000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1264000
CY2022Q1 us-gaap Long Term Investments
LongTermInvestments
47472000
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
35533000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8964000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8629000
CY2022Q1 tgtx Leasehold Interest
LeaseholdInterest
1786000
CY2021Q4 tgtx Leasehold Interest
LeaseholdInterest
1839000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
526000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
600000
CY2022Q1 us-gaap Goodwill
Goodwill
799000
CY2021Q4 us-gaap Goodwill
Goodwill
799000
CY2022Q1 us-gaap Assets
Assets
303028000
CY2021Q4 us-gaap Assets
Assets
379629000
CY2022Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
49668000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
51294000
CY2022Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1873000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1512000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
975000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1492000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1437000
CY2022Q1 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
1623000
CY2021Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
10166000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
54656000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
65384000
CY2022Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
419000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
457000
CY2022Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
67249000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
66788000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10318000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9847000
CY2022Q1 us-gaap Liabilities
Liabilities
132642000
CY2021Q4 us-gaap Liabilities
Liabilities
142476000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
144583334
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
143292043
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
144542025
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
143250734
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
145000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
143000
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1568186000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1565942000
CY2022Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
41309
CY2021Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
41309
CY2022Q1 us-gaap Treasury Stock Value
TreasuryStockValue
234000
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
234000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1397711000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1328698000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
170386000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
237153000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
303028000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
379629000
CY2022Q1 us-gaap Revenues
Revenues
2016000
CY2021Q1 us-gaap Revenues
Revenues
793000
CY2022Q1 tgtx Cost Of Product Revenue
CostOfProductRevenue
237000
CY2021Q1 tgtx Cost Of Product Revenue
CostOfProductRevenue
139000
CY2022Q1 tgtx Non Cash Compensation Research And Development Expenses
NonCashCompensationResearchAndDevelopmentExpenses
1895000
CY2021Q1 tgtx Non Cash Compensation Research And Development Expenses
NonCashCompensationResearchAndDevelopmentExpenses
7511000
CY2022Q1 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
46147000
CY2021Q1 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
55583000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48042000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
63094000
CY2022Q1 tgtx Non Cash Compensation Selling General And Administrative Expenses
NonCashCompensationSellingGeneralAndAdministrativeExpenses
226000
CY2021Q1 tgtx Non Cash Compensation Selling General And Administrative Expenses
NonCashCompensationSellingGeneralAndAdministrativeExpenses
9107000
CY2022Q1 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
20383000
CY2021Q1 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
17655000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
20609000
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
26762000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
68888000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
89995000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-66872000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-89202000
CY2022Q1 us-gaap Interest Expense
InterestExpense
2664000
CY2021Q1 us-gaap Interest Expense
InterestExpense
1898000
CY2022Q1 us-gaap Other Income
OtherIncome
523000
CY2021Q1 us-gaap Other Income
OtherIncome
472000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2141000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1426000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-69013000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-90628000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
134400500
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
131898626
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
519350000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
128000
CY2021Q1 tgtx Offering Costs
OfferingCosts
-183000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
16618000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-90628000
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
445285000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
237153000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
125000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2121000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-69013000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
170386000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-69013000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-90628000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2121000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
16618000
CY2022Q1 us-gaap Depreciation
Depreciation
76000
CY2021Q1 us-gaap Depreciation
Depreciation
59000
CY2022Q1 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
23000
CY2021Q1 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
127000
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
461000
CY2021Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
231000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
53000
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
53000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
683000
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
479000
CY2022Q1 tgtx Change In Fair Value Of Notes Payable
ChangeInFairValueOfNotesPayable
178000
CY2021Q1 tgtx Change In Fair Value Of Notes Payable
ChangeInFairValueOfNotesPayable
58000
CY2022Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-6759000
CY2021Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
4107000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-487000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
771000
CY2022Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-10170000
CY2021Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
904000
CY2022Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-492000
CY2021Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-507000
CY2022Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
539000
CY2021Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-3717000
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-38000
CY2021Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-38000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-68689000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-81355000
CY2022Q1 tgtx Proceeds From Maturities
ProceedsFromMaturities
13225000
CY2021Q1 tgtx Proceeds From Maturities
ProceedsFromMaturities
17000000
CY2022Q1 tgtx Payments To Acquire Held To Maturity Securities Short Term
PaymentsToAcquireHeldToMaturitySecuritiesShortTerm
56889000
CY2021Q1 tgtx Payments To Acquire Held To Maturity Securities Short Term
PaymentsToAcquireHeldToMaturitySecuritiesShortTerm
17447000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
67000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-43671000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-514000
CY2022Q1 us-gaap Proceeds From Repayments Of Secured Debt
ProceedsFromRepaymentsOfSecuredDebt
-975000
CY2022Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
125000
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
128000
CY2021Q1 tgtx Repayment Of Offering Costs
RepaymentOfOfferingCosts
183000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-850000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-55000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-113210000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-81924000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
300151000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
554698000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
186941000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
472774000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
185676000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
471514000
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
1265000
CY2021Q1 us-gaap Restricted Cash
RestrictedCash
1260000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
186941000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
472774000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
1584000
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
769000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1400000000
CY2022Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
280700000
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12657717
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12129734
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12657717
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12129734
CY2022Q1 tgtx Revenue Gross
RevenueGross
3419000
CY2021Q1 tgtx Revenue Gross
RevenueGross
906000
CY2022Q1 us-gaap Administrative Fees Expense
AdministrativeFeesExpense
250000
CY2021Q1 us-gaap Administrative Fees Expense
AdministrativeFeesExpense
75000
CY2022Q1 tgtx Trade Discounts And Allowances
TradeDiscountsAndAllowances
220000
CY2021Q1 tgtx Trade Discounts And Allowances
TradeDiscountsAndAllowances
37000
CY2022Q1 tgtx Government Rebates And Co Payment Assistance
GovernmentRebatesAndCoPaymentAssistance
229000
CY2021Q1 tgtx Government Rebates And Co Payment Assistance
GovernmentRebatesAndCoPaymentAssistance
35000
CY2022Q1 tgtx Sales Returns And Allowances
SalesReturnsAndAllowances
742000
CY2021Q1 tgtx Sales Returns And Allowances
SalesReturnsAndAllowances
4000
CY2022Q1 tgtx Gross To Net Adjustments
GrossToNetAdjustments
1441000
CY2021Q1 tgtx Gross To Net Adjustments
GrossToNetAdjustments
151000
CY2022Q1 tgtx Net Product Revenue
NetProductRevenue
1978000
CY2021Q1 tgtx Net Product Revenue
NetProductRevenue
755000
CY2022Q1 tgtx Gross Net Accruals
GrossNetAccruals
1300000
CY2022Q1 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
94997000
CY2022Q1 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
1000
CY2022Q1 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
1011000
CY2022Q1 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
93987000
CY2021Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
51409000
CY2021Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
164000
CY2021Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
51245000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10318000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9847000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
11810000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
11284000
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
360000
CY2022Q1 tgtx Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Interest Accrued Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings
262000
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-440000
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
182000
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2100000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
16600000
CY2022Q1 us-gaap Other Long Term Debt
OtherLongTermDebt
70000000
CY2021Q4 us-gaap Other Long Term Debt
OtherLongTermDebt
70000000
CY2022Q1 tgtx End Of Term Fee
EndOfTermFee
4165000
CY2021Q4 tgtx End Of Term Fee
EndOfTermFee
5140000
CY2022Q1 tgtx Long Term Debt Gross
LongTermDebtGross
74165000
CY2021Q4 tgtx Long Term Debt Gross
LongTermDebtGross
75140000
CY2022Q1 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
6916000
CY2021Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
7377000
CY2022Q1 us-gaap Long Term Debt
LongTermDebt
67249000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
67763000
CY2022Q1 tgtx Long Term Debt Excluding Principal Payments
LongTermDebtExcludingPrincipalPayments
67249000
CY2021Q4 tgtx Long Term Debt Excluding Principal Payments
LongTermDebtExcludingPrincipalPayments
67763000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
975000
CY2022Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
67249000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
66788000
CY2022Q1 tgtx Percentage Of Occupancy
PercentageOfOccupancy
0.63
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
11800000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9000000.0
CY2022Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P2Y
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
514000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
532000
CY2022Q1 us-gaap Lease Cost
LeaseCost
514000
CY2021Q1 us-gaap Lease Cost
LeaseCost
532000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1492000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1437000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2125000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2162000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1553000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1899000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1932000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
8261000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
17932000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6122000
CY2022Q1 tgtx Operating Lease Liability Incremental Borrowing Rate
OperatingLeaseLiabilityIncrementalBorrowingRate
11810000

Files In Submission

Name View Source Status
0001558370-22-008130-index-headers.html Edgar Link pending
0001558370-22-008130-index.html Edgar Link pending
0001558370-22-008130.txt Edgar Link pending
0001558370-22-008130-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tgtx-20220331.xsd Edgar Link pending
tgtx-20220331x10q.htm Edgar Link pending
tgtx-20220331x10q_htm.xml Edgar Link completed
tgtx-20220331xex31d1.htm Edgar Link pending
tgtx-20220331xex31d2.htm Edgar Link pending
tgtx-20220331xex32d1.htm Edgar Link pending
tgtx-20220331xex32d2.htm Edgar Link pending
tgtx-20220331_cal.xml Edgar Link unprocessable
tgtx-20220331_def.xml Edgar Link unprocessable
tgtx-20220331_lab.xml Edgar Link unprocessable
tgtx-20220331_pre.xml Edgar Link unprocessable